Abstract
Metastatic breast cancer is one of the attributed leading causes of women deaths worldwide. Accurate diagnosis to the spread of breast cancer to axillary lymph nodes (ALNs) is done by breast pathologist, utilizing the microscope to inspect and then providing the biopsy report. Because such a diagnosis process requires special expertise, there is a need for artificial intelligence-based tools to assist breast pathologists to automatically detect breast cancer metastases. This study aims to detect breast cancer metastasized to ALN with end-to-end deep learning (DL). Also, we utilize several DL architectures, including DenseNet121, ResNet50, VGG16, Xception as well as a customized lightweight convolutional neural network. We evaluate the DL models on NVIDIA GeForce RTX 2080Ti GPU using 114 processed microscopic images pertaining to ALN metastases in breast cancer patients. Compared to all DL models employed in this study, experimental results show that DenseNet121 generates the highest performance results (64– 68%) based on AUC and accuracy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by KAKENHI 19H05270, 20K12067, 20H04848.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
It does not include any newly obtained data
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data was downloaded from public domain
